Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Overall Survival
87%
Breast Cancer
72%
Capecitabine
71%
Neoplasm
68%
Progression Free Survival
57%
Patient
52%
Hazard Ratio
49%
Stomach Cancer
47%
Adjuvant Chemotherapy
43%
Gemcitabine
43%
Pancreas Adenocarcinoma
40%
Recurrent Disease
40%
Neoadjuvant Chemotherapy
39%
Fluorouracil
38%
Adenocarcinoma
38%
Folinic Acid
37%
Oxaliplatin
36%
Inpatient
36%
Ampulla of Vater
35%
Triple Negative Breast Cancer
35%
Retroperitoneal Lymph Node Dissection
32%
Uvomorulin
32%
Lymphocyte
31%
Epidermal Growth Factor Receptor
30%
Malignant Neoplasm
28%
Phase II Trials
28%
Disease Free Survival
25%
Cytotoxic T-Cell
24%
Palpitations
23%
Eczema
23%
Clinical Significance
23%
Liver Metastasis
23%
Retrospective Cohort Study
23%
Lymph Node
23%
Association
23%
Carcinomatous Peritonitis
23%
Non Small Cell Lung Cancer
23%
Breast Tumor
23%
Metastatic Breast Cancer
23%
Palbociclib
23%
Skeletal Muscle
23%
Brain Metastasis
23%
Proportional Hazards Model
20%
Biological Marker
20%
Neutropenia
20%
Recurrence Free Survival
19%
Thyroid Gland
19%
Survival
18%
Prognostic Factor
18%
Immune Checkpoint Inhibitor
17%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Progression Free Survival
76%
Fluorouracil
61%
Gemcitabine
55%
Capecitabine
47%
Folinic Acid
44%
Neoplasm
44%
Adenocarcinoma
38%
Chemotherapy
37%
First-Line Chemotherapy
37%
Metastatic Breast Cancer
35%
Palbociclib
35%
Triple Negative Breast Cancer
35%
Immunoreactive Insulin
31%
Immune Checkpoint Inhibitor
29%
Pancreas Adenocarcinoma
28%
Phase II Trials
28%
Neutropenia
25%
Irinotecan Sucrosofate
24%
Cohort Study
23%
Pancreas Cancer
23%
Capecitabine
23%
Atezolizumab
23%
Cisplatin
23%
Biliary Tract Cancer
23%
Epidermal Growth Factor Receptor
23%
Recurrent Disease
21%
Survival
18%
Uvomorulin
17%
Oxaliplatin
17%
Irinotecan
17%
Gamma Urogastrone
16%
Letrozole
15%
Recurrence Free Survival
14%
Immunotherapy
13%
Breast Cancer
13%
Monotherapy
13%
Oxaliplatin
12%
Malignant Neoplasm
12%
Prognosis
12%
Abdominal Cancer
11%
Thyroid Disease
11%
Metastatic Breast Cancer
11%
Non Small Cell Lung Cancer
11%
CA 19-9 Antigen
11%
Gemcitabine
11%
Heart Palpitation
11%
Carcinomatous Peritonitis
11%
Stomach Cancer
11%
Palbociclib
11%
Immunology and Microbiology
Overall Survival
45%
Programmed Death-Ligand 1
42%
Progression Free Survival
34%
Cytotoxic T-Cell
23%
Atezolizumab
23%
Lymph Node
17%
Recurrence Free Survival
17%
Disease Free Survival
14%
Lymphocyte
13%
Lymphocyte Count
11%
Ampulla of Vater
11%
CA 19-9 Antigen
11%
Neutrophil Granulocyte
11%
Association
11%
Mortality
11%
Interleukin 6
11%
Skeletal Muscle
11%
Granzyme B
11%
Tumor-Infiltrating Lymphocytes
11%
Nivolumab
11%
Gene Expression Assay
11%
Lymphopenia
8%
CXCL10
7%
Brain Derived Neurotrophic Factor
7%
Survival Rate
7%
Immunotherapy
6%
Blood Plasma
6%
Cadherin
5%
MUC1
5%
Cancer Stem Cell
5%
Activating Transcription Factor
5%
Cell Marker
5%
MUC2
5%
Epithelial Mesenchymal Transition
5%
ABCG2
5%
Programmed Death 1 Ligand 1
5%
Upregulation
5%
Neutrophil
5%
Lymphocyte
5%
ELISA
5%
Immunocompetent Cell
5%